- Home
- SLM vs DYN Comparison
SLM vs DYN Comparison
Compare SLM & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLM | DYN |
|---|---|---|
| Founded | 1972 | 1984 |
| Country | United States | United States |
| Employees | 1788 | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLM | DYN |
|---|---|---|
| Price | $25.17 | $25.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $31.09 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 3.0M | 2.6M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.35 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $6.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.77 | $8.88 |
| 52 Week High | $33.17 | $25.00 |
Technical Indicators
Market Signals| Indicator | SLM | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 67.91 |
| Support Level | $21.00 | $16.47 |
| Resistance Level | $26.01 | N/A |
| Average True Range (ATR) | 0.80 | 1.43 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 79.23 | 85.85 |
Price Performance
Historical ComparisonAbout SLM SLM Corporation
SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.